Patient records go digital to 'co-ordinate care'
All patient records at a hospital are to go digital as part of a major step "in modernising patient care".
The new Electronic Patient Record (EPR) will be switched on at Northampton General Hospital (NGH) from Saturday 28 June.
It has been developed by the software system Nervecentre, and is designed to bring all patient notes and information into "one single, secure digital format".
William Monaghan, from NGH, described it as a "pivotal moment" and said he hoped it would mean "safer and more co-ordinated care".
A hospital spokesperson said the electronic system would "enable clinical teams to access real-time information about a patient's care, helping them make quicker, safer and better-informed decisions".
Patient records are currently stored in a combination of paper files and digital systems, but will be replaced by "a central, streamlined platform that enhances efficiency and reduces duplication".
Mr Monaghan, group chief digital information officer, said: "This is a pivotal moment for NGH and our patients.
"The new EPR system puts essential information at our clinical teams' fingertips, helping them deliver safer, more co-ordinated care.
"While there may be a few teething problems as we go live, this investment in digital infrastructure will transform how we work, giving our teams more time to focus on what matters most: caring for patients."
The hospital said staff would be using secure, hospital-owned mobile devices, like tablets and iPhones, at patients' bedsides.
It means staff will be able to view the latest medical information instantly, spend less time on administration, avoid asking patients to repeat their history many times - and improve co-ordination between departments and services.
All patient information will be kept secure, it confirmed.
Follow Northamptonshire news on BBC Sounds, Facebook, Instagram and X.
Hospital's A&E told to make urgent improvements
Hospital staff invited to resign to reduce workforce
Hospital ward is 'safe' despite concern over falls
Northampton General Hospital
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Women less likely to get life-saving care for deadly heart condition
A new analysis reveals that women are less likely than men to receive treatment for aortic stenosis, a potentially fatal heart condition. Researchers discovered that women are 11% less likely to be referred to a hospital specialist following a diagnosis of the heart valve disease. Academics noted that the findings reveal "inequities in management and care of this common and serious condition." The study also found differences in care among south Asian and black patients, as well as those from poorer backgrounds. Aortic stenosis, a narrowing of the aortic valve or the area immediately around it, leads to obstruction of the blood flow from the heart, which leads to symptoms including dizziness, fatigue, chest pain and breathlessness. The condition is more common in elderly people. It is not possible to reverse but treatments can include a transcatheter aortic valve implantation (TAVI) or valve replacement surgery. If left untreated it can lead to serious complications, including heart failure, heart rhythm abnormalities, and death. The analysis suggests some people are less likely to receive this treatment. Experts from the University of Leicester examined GP data on 155,000 people diagnosed with aortic stenosis between 2000 and 2022 in England. Presenting their findings to the British Cardiovascular Society conference in Manchester, experts said as well as women being less likely to be referred for hospital care, they are 39% less likely to have a procedure to replace their aortic valve. Researchers also found people living in poorer neighbourhoods are 7% less likely to be referred for hospital care after a diagnosis compared to people from wealthier neighbourhoods. Meanwhile, black patients are 48% less likely to undergo a procedure to replace their aortic valve compared to white patients. South Asian patients are 27% less likely to undergo a procedure compared to their white counterparts, according to the study, which was funded by the National Institute for Health and Care Research (NIHR) and supported by NIHR Leicester Biomedical Research Centre. Dr Anvesha Singh, associate professor at the University of Leicester and consultant cardiologist, who was involved in the research, said: 'Previous studies have shown lower rates of valve replacement in women, and clinicians had assumed that women were less likely to be diagnosed with aortic stenosis. 'This analysis using large, real-world data clearly shows that this is not the case, giving us the clearest picture yet of what is happening in day-to-day clinical practice. 'Our study highlights potential inequities in management and care of this common and serious condition. More research is needed to understand the reasons for this and the true prevalence of aortic stenosis in different groups.' Dr Sonya Babu-Narayan, clinical director at the British Heart Foundation, which supported the research, and consultant cardiologist, said: 'This study of over 150,000 GP records has unveiled disparities in access to aortic valve treatment for women, south Asian and black people, and people living in more deprived communities. 'We don't yet have the full picture, but these findings are concerning and we need more research to understand what is driving the differences seen. 'This will be crucial to enable action to address any underlying causes stopping some people from having access to the heart valve treatment and care they need, when they need it.'
Yahoo
2 hours ago
- Yahoo
ADHD drugs back in the spotlight after study debunks rising prevalence
An increasing number of patients are seeking support for attention-deficit/hyperactivity disorder (ADHD), with pharmacological-based treatments an important part of medical care for the neurodevelopmental condition. A study published this week in the Journal of Affective Disorders has found that greater awareness and acceptance around the disorder has led to more people seeking help. The research, led by a team at King's College, London, debunks claims that the disorder is 'naturally' on the rise. The data comes as a national taskforce in England investigates what this rising demand for support means for the NHS. Figures published in May 2025 by NHS England estimated there were nearly 2.5 million people in England with ADHD. This includes more than 550,000 currently waiting for an assessment. Every month 20,000 more people are referred for support, a rise of 13% compared to last year. Pharmaceutical Technology looks at some of the current options in the UK and casts an eye ahead to what the future drug landscape might contain. The first choice for patients with ADHD is methylphenidate, which belongs to a class of drugs called central nervous system (CNS) stimulants. The drug, which works by blocking the reuptake of norepinephrine and dopamine, increases activity in the brain, including regions associated with attention and behaviour. It is known under the brand names Ritalin, manufactured by Novartis, and Johnson and Johnson's Concerta. There is also Equasym and Xenidate, among others. Lisdexamfetamine dimesylate is also used to treat patients with ADHD. Like methylphenidate, lisdexamfetamine is a CNS stimulant and acts as a norepinephrine and dopamine reuptake inhibitor (NDRI). This drug is known under the brand name, among others, as Elvanse and Vyvanse, both manufactured by Takeda. While stimulants are fast acting, with side effects felt soon after administration, non-stimulant drugs take longer, yet can offer an alternative if drugs like methylphenidate and lisdexamfetamine dimesylate do not work. While improving, access to pharmacological-based treatments is still impaired amid an ongoing global shortage that began in September 2023. Methylphenidate and lisdexamfetamine were primarily affected – the shortage arising due to a combination of manufacturing issues and increased global demand. A separate study published in The American Journal of Managed Care in March suggested that overdiagnosis of ADHD is fuelling the shortage of stimulation medications. One of the most advanced candidate drugs, and one with notable buzz surrounding it, is Axsome's Sunosi (solriamfetol). Sunosi, which is also an NDRI but not a conventional stimulant, met its primary endpoint in a Phase III trial (NCT05972044) earlier this year. The medication led to a 45% drop in ADHD symptoms. As measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS), 150mg Sunosi dosed achieved average reductions from baseline of 17.7 points, compared to 14.3 points for placebo. Sunosi is already approved in the UK to treat excessive daytime sleepiness (EDS) in adults with narcolepsy, with or without cataplexy. Certain patients with obstructive sleep apnoea (OSA) are also eligible to take the medication. In 2022, Axsome paid $53m up front to acquire Sunosi from Jazz Pharmaceuticals. A drug with a recent approval extension in the US, though not the UK, was Supernus Pharmaceuticals' Qelbree (viloxazine extended-release capsules). The mechanism of action of Qelbree, though unclear, is thought to be through inhibiting the reuptake of norepinephrine. Originally approved for children in 2021, the FDA updated the drug's label in January this year to include adults. ADHD treatments were in the political crosshairs in the US recently. The disorder, along with autism, was singled out by the Trump administration for an 'over-utilisation of medication'. Pharmaceutical intervention remains a helpful part of managing the disorder, though it is part of a combination of treatments that also include coaching and lifestyle changes. "ADHD drugs back in the spotlight after study debunks rising prevalence" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Women on blockbuster weight loss drugs warned to use effective contraception
Pregnant women should not take weight loss drugs, the UK's medicines regulator warned amid concerns that people are using the so-called 'skinny jabs' in unsafe ways. The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby. 'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said. Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said. Related Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD). 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement. 'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added. Related France won't pay for weight loss drug Wegovy. What about other European countries? In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro. The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity. Related Why are 1 in 10 French women still smoking during pregnancy despite the health risks? But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.
